Literature DB >> 22044283

Role of α1- and α2-GABA(A) receptors in mediating the respiratory changes associated with benzodiazepine sedation.

S Masneuf1, J Buetler, C Koester, F Crestani.   

Abstract

BACKGROUND AND
PURPOSE: The molecular substrates underlying the respiratory changes associated with benzodiazepine sedation are unknown. We examined the effects of different doses of diazepam and alprazolam on resting breathing in wild-type (WT) mice and clarified the contribution of α1- and α2-GABA(A) receptors, which mediate the sedative and muscle relaxant action of diazepam, respectively, to these drug effects using point-mutated mice possessing either α1H101R- or α2H101R-GABA(A) receptors insensitive to benzodiazepine. EXPERIMENTAL APPROACH: Room air breathing was monitored using whole-body plethysmography. Different groups of WT mice were injected i.p. with diazepam (1-100 mg·kg(-1) ), alprazolam (0.3, 1 or 3 mg·kg(-1) ) or vehicle. α1H101R and α2H101R mice received 1 or 10 mg·kg(-1) diazepam or 0.3 or 3 mg·kg(-1) alprazolam. Respiratory frequency, tidal volume, time of expiration and time of inspiration before and 20 min after drug injection were analysed. KEY
RESULTS: Diazepam (10 mg·kg(-1) ) decreased the time of expiration, thereby increasing the resting respiratory frequency, in WT and α2H101R mice, but not in α1H101R mice. The time of inspiration was shortened in WT and α1H101R mice, but not in α2H101R mice. Alprazolam (1-3 mg·kg(-1) ) stimulated the respiratory frequency by shortening expiration and inspiration duration in WT mice. This tachypnoeic effect was partially conserved in α1H101R mice while absent in α2H101R mice. CONCLUSIONS AND IMPLICATIONS: These results identify a specific role for α1-GABA(A) receptors and α2-GABA(A) receptors in mediating the shortening by benzodiazepines of the expiratory and inspiratory phase of resting breathing respectively.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22044283      PMCID: PMC3415658          DOI: 10.1111/j.1476-5381.2011.01763.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  52 in total

1.  Resolving differences in GABAA receptor mutant mouse studies.

Authors:  F Crestani; J R Martin; H Möhler; U Rudolph
Journal:  Nat Neurosci       Date:  2000-11       Impact factor: 24.884

Review 2.  Neuropharmacology of control of respiratory rhythm and pattern in mature mammals.

Authors:  A Haji; R Takeda; M Okazaki
Journal:  Pharmacol Ther       Date:  2000-06       Impact factor: 12.310

3.  Molecular and neuronal substrate for the selective attenuation of anxiety.

Authors:  K Löw; F Crestani; R Keist; D Benke; I Brünig; J A Benson; J M Fritschy; T Rülicke; H Bluethmann; H Möhler; U Rudolph
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

4.  Positioning of the alpha-subunit isoforms confers a functional signature to gamma-aminobutyric acid type A receptors.

Authors:  Frédéric Minier; Erwin Sigel
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-10       Impact factor: 11.205

5.  Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux.

Authors:  A J Smith; L Alder; J Silk; C Adkins; A E Fletcher; T Scales; J Kerby; G Marshall; K A Wafford; R M McKernan; J R Atack
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

6.  Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes.

Authors:  U Rudolph; F Crestani; D Benke; I Brünig; J A Benson; J M Fritschy; J R Martin; H Bluethmann; H Möhler
Journal:  Nature       Date:  1999-10-21       Impact factor: 49.962

7.  Sleep apnea and effect of chemostimulation on breathing instability in mice.

Authors:  Akira Nakamura; Yasuichiro Fukuda; Tomoyuki Kuwaki
Journal:  J Appl Physiol (1985)       Date:  2002-10-25

8.  Molecular targets for the myorelaxant action of diazepam.

Authors:  F Crestani; K Löw; R Keist; M Mandelli; H Möhler; U Rudolph
Journal:  Mol Pharmacol       Date:  2001-03       Impact factor: 4.436

9.  GABA A mediated inhibition and post-inspiratory pattern of laryngeal constrictor motoneurons in rat.

Authors:  Qi-Jian Sun; Robert G Berkowitz; Paul M Pilowsky
Journal:  Respir Physiol Neurobiol       Date:  2008-04-01       Impact factor: 1.931

10.  Contribution of the alpha1-GABA(A) receptor subtype to the pharmacological actions of benzodiazepine site inverse agonists.

Authors:  F Crestani; R Assandri; M Täuber; J R Martin; U Rudolph
Journal:  Neuropharmacology       Date:  2002-09       Impact factor: 5.250

View more
  3 in total

1.  Voltage-clamp evidence of GABAA receptor subunit-specific effects: pharmacodynamic fingerprint of chlornordiazepam, the major active metabolite of mexazolam, as compared to alprazolam, bromazepam, and zolpidem.

Authors:  Hélder Fernandes; Vânia Batalha; Ellen Braksator; Simon Hebeisen; Maria João Bonifácio; Maria Augusta Vieira-Coelho; Patrício Soares-da-Silva
Journal:  Pharmacol Rep       Date:  2022-09-12       Impact factor: 3.919

2.  The association of serotonin reuptake inhibitors and benzodiazepines with ictal central apnea.

Authors:  Nuria Lacuey; Rita Martins; Laura Vilella; Johnson P Hampson; M R Sandhya Rani; Kingman Strohl; Anita Zaremba; Jaison S Hampson; Rup K Sainju; Daniel Friedman; Maromi Nei; Catherine Scott; Brian K Gehlbach; Norma J Hupp; Stephan Schuele; Jennifer Ogren; Ronald M Harper; Luke Allen; Beate Diehl; Lisa M Bateman; Orrin Devinsky; George B Richerson; Samden Lhatoo
Journal:  Epilepsy Behav       Date:  2019-07-10       Impact factor: 2.937

3.  The Direct Actions of GABA, 2'-Methoxy-6-Methylflavone and General Anaesthetics at β3γ2L GABAA Receptors: Evidence for Receptors with Different Subunit Stoichiometries.

Authors:  Han Chow Chua; Nathan L Absalom; Jane R Hanrahan; Raja Viswas; Mary Chebib
Journal:  PLoS One       Date:  2015-10-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.